Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety of Pembrolizumab Every Six Weeks in Relapsed/Refractory Classical Hodgkin Lymphoma or Primary Mediastinal B-Cell Lymphoma: Keynote-B68 Update

Blood (2024) 144 (Supplement 1): 3046.

https://doi.org/10.1182/blood-2024-200323

Published: 2024

Journal Articles

Keynote-B68: Updated Efficacy and Safety of Pembrolizumab Every Six Weeks in Relapsed/Refractory Classical Hodgkin Lymphoma or Primary Mediastinal B-Cell Lymphoma

Blood (2023) 142 (Supplement 1): 4442.

https://doi.org/10.1182/blood-2023-186800

Published: 2023

Journal Articles

Ibrutinib Alone or in Combination with R-CHOP Chemoimmunotherapy in Relapsed or Refractory Primary Central Nervous System Lymphoma (rrPCNSL): A «Real-Life» Study

Blood (2022) 140 (Supplement 1): 6678–6680.

https://doi.org/10.1182/blood-2022-170143

Published: 2022

Journal Articles

Molecular Characterization of Diffuse Large B-Cell Lymphoma Associated to Hepatitis C Virus Infection

Blood (2021) 138 (Supplement 1): 2402.

https://doi.org/10.1182/blood-2021-152636

Published: 2021

Journal Articles

Five-Year Survival and Durability Results of the Phase 2 Trial Using the Begev Regimen (Bendamustine, Gemcitabine And Vinorelbine)As Salvage Therapy Prior to Autologous Stem Cell Transplant for Relapsed/Refractory Classic Hodgkin Lymphoma

Armando Santoro, MD, Rita Mazza, MD, Alessandro Pulsoni, MD, Alessandro Re, MD, Maurizio Bonfichi, MD, Vittorio Ruggero Zilioli, Flavia Salvi, Antonella Anastasia, MD, Stefano Luminari, MD, Manuel Gotti, MD, Annalisa Peli, MD, Anna Marina Liberati, MD, Nicola Di Renzo, MD, Luca Castagna, MD, Laura Giordano, Carmelo Carlo-Stella, MD

Blood (2018) 132 (Supplement 1): 1628.

https://doi.org/10.1182/blood-2018-99-118931

Published: 2018

Journal Articles

Lenalidomide Maintenance after Autologous Transplantation Prolongs PFS in Young MCL Patients: Results of the Randomized Phase III MCL 0208 Trial from Fondazione Italiana Linfomi (FIL)

Blood (2018) 132 (Supplement 1): 401.

https://doi.org/10.1182/blood-2018-99-110289

Published: 2018

Journal Articles

ABC Subtype, TP53 Mutation and BCL2 Overexpression are Associated with a Worse Outcome in Untreated Poor-Risk Young Diffuse Large B-Cell Lymphoma: Results from the Frontline Phase III BIO-DLBCL04 Study of the Fondazione Italiana Linfomi

Blood (2017) 130 (Supplement 1): 4010.

https://doi.org/10.1182/blood.V130.Suppl_1.4010.4010

Published: 2017

Journal Articles

Multicenter Retrospective Observational Study to Assess the Clinical Characteristics and the Outcome of Patients with Relapsed or Refractory Mantle Cell Non-Hodgkin's Lymphoma Treated in Italy According to the Ibrutinib Named Patient Program

Vittorio Stefoni, Federico Sottotetti, Manuel Gotti, Michele Spina, Stefano Volpetti, Simone Ferrero, Francesco Spina, MD, Francesco Pisani, Michele Merli, Carlo Visco, MD, Rossella Paolini, Vittorio Ruggero Zilioli, Luca Baldini, MD Prof, Nicola Di Renzo, Patrizia Tosi, Nicola Cascavilla, MD, Stefano Molica, MD, Lisa Argnani, Pier Luigi Zinzani, MD PhD

Blood (2016) 128 (22): 2985.

https://doi.org/10.1182/blood.V128.22.2985.2985

Published: 2016

Journal Articles

Rituximab, Bendamustine and Cytarabine (RBAC500) As Induction Therapy in Elderly Patients with Mantle Cell Lymphoma: Final Results of a Phase 2 Study from the Fondazione Italiana Linfomi

Blood (2016) 128 (22): 472.

https://doi.org/10.1182/blood.V128.22.472.472

Published: 2016

Journal Articles

LNK mutations in familial myeloproliferative neoplasms

Elisa Rumi, Ashot S. Harutyunyan, Daniela Pietra, Jelena D. Milosevic Feenstra, Chiara Cavalloni, Elisa Roncoroni, Ilaria Casetti, Marta Bellini, Chiara Milanesi, Maria C. Renna, Manuel Gotti, Cesare Astori, Robert Kralovics, Mario Cazzola

Blood (2016) 128 (1): 144–145.

https://doi.org/10.1182/blood-2016-04-711150

Published: 2016

Journal Articles

Remarkable Clinical Efficacy, Stem Cell Mobilization Activity and Good Toxicity Profile of the Novel Begev Regimen (Bendamustine, Gemcitabine And Vinorelbine) Used As Salvage Therapy Prior to Autologous Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma

Armando Santoro, MD, Rita Mazza, MD, Alessandro Pulsoni, MD, Alessandro Re, Maurizio Bonfichi, MD, Vittorio Ruggero Zilioli, MD, Flavia Salvi, MD, Antonella Anastasia, Stefano Luminari, MD, Manuel Gotti, MD, Annalisa Peli, Anna Marina Liberati, MD, Nicola Di Renzo, Luca Castagna, Laura Giordano, Carmelo Carlo-Stella, MD

Blood (2015) 126 (23): 581.

https://doi.org/10.1182/blood.V126.23.581.581

Published: 2015

Journal Articles

The Prognostic Role of Cell of Origin Profile and Myc Expression Assessed By Immunohistochemistry in Young High-Risk Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Results of First-Line Randomized BIO-DLCL04 Trial of Fondazione Italiana Linfomi (FIL)

Annalisa Chiappella, Claudio Agostinelli, Maurizio Martelli, Simona Righi, Andrea Evangelista, Emanuele Angelucci, Monica Balzarotti, Angelo Michele Carella, Manuel Gotti, Domenico Novero, MD, Giuseppe Rossi, MD, Caterina Stelitano, Marco Ladetto, Gianluca Gaidano, Stefano A Pileri, Umberto Vitolo

Blood (2015) 126 (23): 5041.

https://doi.org/10.1182/blood.V126.23.5041.5041

Published: 2015

Journal Articles

Outcome of Transformed Marginal Zone Lymphomas Treated in the Rituximab Era

Chiara Rusconi, MD, Maria Luisa Guerrera, MD, Alessandra Tedeschi, MD, Michelle Zancanella, MD, Manuel Gotti, MD, Michele Nichelatti, Sara Rattotti, MD, Lara Crucitti, MD, Marco Frigeni, Erika Meli, MD, Paola Picardi, MD, Anna Maria Frustaci, MD, Roberta Sciarra, Vittorio Ruggero Zilioli, MD, Periana Minga, MD, Marco Paulli, Roberto Cairoli, MD, Luca Arcaini

Blood (2015) 126 (23): 5098.

https://doi.org/10.1182/blood.V126.23.5098.5098

Published: 2015

Journal Articles

Utility of baseline 18FDG-PET/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma

Blood (2015) 126 (8): 950–956.

https://doi.org/10.1182/blood-2014-12-616474

Published: 2015

Includes: Supplemental data

Journal Articles

Non-Hodgkin's Lymphomas Associated With Positive Hepatitis-C Virus Infection: A Prospective Multicentric Observational Study On Behalf Of The “Rete Ematologica Lombarda/Hematology Network Of Lombardia Region”

Sara Rattotti, Luca Arcaini, Virginia Valeria Ferretti, Andrea Rossi, Stefano Fogazzi, Antonino Greco, Luca Baldini, Monica Balzarotti, Pietro Pioltelli, Maurizio Bonfichi, Marzia Varettoni, Manuel Gotti, Lucia Farina, Andrés J.M. Ferreri, Daniele Laszlo, Enrica Morra, MD

Blood (2013) 122 (21): 3003.

https://doi.org/10.1182/blood.V122.21.3003.3003

Published: 2013

Journal Articles

Impact Of Bone Marrow Involvement On Outcome Of Young Patients With High-Risk Diffuse Large B-Cell Lymphoma (DLBCL) Treated In The Phase III Randomized Trial (DLCL04) With Rituximab Dose-Dense Chemotherapy Followed By Intensified High-Dose Chemotherapy and Autologous Stem Cell Transplantation (HDC+ASCT) Or Standard Rituximab Dose Dense Chemotherapy: A Study of The Fondazione Italiana Linfomi (FIL)

Blood (2013) 122 (21): 4340.

https://doi.org/10.1182/blood.V122.21.4340.4340

Published: 2013

Journal Articles

Do Leukemic Cells and Mesenchymal Stem Cells (MSCs) From AML Patients Share The Same Chromosomal Defect? A Cytogenetics, FISH and aCGH/Snpa Study

Paolo Bernasconi, Irene Dambruoso, Manuel Gotti, Marina Boni, Rita Zappatore, PhD, Celeste Calvello, BSc, Claudia del Fante, Gianluca Viarengo, MD, Marilla Cervio, Cesare Perotti, MD

Blood (2013) 122 (21): 2602.

https://doi.org/10.1182/blood.V122.21.2602.2602

Published: 2013

Journal Articles

MYD88 (L265P) mutation is an independent risk factor for progression in patients with IgM monoclonal gammopathy of undetermined significance

Marzia Varettoni, Silvia Zibellini, Luca Arcaini, Emanuela Boveri, Sara Rattotti, Cristiana Pascutto, Silvia Mangiacavalli, Manuel Gotti, Lara Pochintesta, Marco Paulli, Mario Cazzola

Blood (2013) 122 (13): 2284–2285.

https://doi.org/10.1182/blood-2013-07-513366

Published: 2013

Journal Articles

Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenström’s macroglobulinemia and related lymphoid neoplasms

Marzia Varettoni, Luca Arcaini, Silvia Zibellini, Emanuela Boveri, Sara Rattotti, Roberta Riboni, Alessandro Corso, Ester Orlandi, Maurizio Bonfichi, Manuel Gotti, Cristiana Pascutto, Silvia Mangiacavalli, Giorgio Croci, Valeria Fiaccadori, Lucia Morello, Maria Luisa Guerrera, Marco Paulli, Mario Cazzola

Blood (2013) 121 (13): 2522–2528.

https://doi.org/10.1182/blood-2012-09-457101

Published: 2013

Journal Articles

Clinical Significance of Tumor-Associated Macrophages in Early-Stage Hodgkin's Lymphoma.

Manuel Gotti, Marta Nicola, Valeria Fiaccadori, Elisa Bono, Marco Lucioni, Maurizio Bonfichi, Marzia Varettoni, Cristiana Pascutto, Luca Arcaini, Marco Paulli, Mario Cazzola

Blood (2012) 120 (21): 2638.

https://doi.org/10.1182/blood.V120.21.2638.2638

Published: 2012

NARROW

Efficacy and Safety of Pembrolizumab Every Six Weeks in Relapsed/Refractory Classical Hodgkin Lymphoma or Primary Mediastinal B-Cell Lymphoma: Keynote-B68 Update

Keynote-B68: Updated Efficacy and Safety of Pembrolizumab Every Six Weeks in Relapsed/Refractory Classical Hodgkin Lymphoma or Primary Mediastinal B-Cell Lymphoma

Ibrutinib Alone or in Combination with R-CHOP Chemoimmunotherapy in Relapsed or Refractory Primary Central Nervous System Lymphoma (rrPCNSL): A «Real-Life» Study

Molecular Characterization of Diffuse Large B-Cell Lymphoma Associated to Hepatitis C Virus Infection

Five-Year Survival and Durability Results of the Phase 2 Trial Using the Begev Regimen (Bendamustine, Gemcitabine And Vinorelbine)As Salvage Therapy Prior to Autologous Stem Cell Transplant for Relapsed/Refractory Classic Hodgkin Lymphoma

Lenalidomide Maintenance after Autologous Transplantation Prolongs PFS in Young MCL Patients: Results of the Randomized Phase III MCL 0208 Trial from Fondazione Italiana Linfomi (FIL)

ABC Subtype, TP53 Mutation and BCL2 Overexpression are Associated with a Worse Outcome in Untreated Poor-Risk Young Diffuse Large B-Cell Lymphoma: Results from the Frontline Phase III BIO-DLBCL04 Study of the Fondazione Italiana Linfomi

Multicenter Retrospective Observational Study to Assess the Clinical Characteristics and the Outcome of Patients with Relapsed or Refractory Mantle Cell Non-Hodgkin's Lymphoma Treated in Italy According to the Ibrutinib Named Patient Program

Rituximab, Bendamustine and Cytarabine (RBAC500) As Induction Therapy in Elderly Patients with Mantle Cell Lymphoma: Final Results of a Phase 2 Study from the Fondazione Italiana Linfomi

LNK mutations in familial myeloproliferative neoplasms

Remarkable Clinical Efficacy, Stem Cell Mobilization Activity and Good Toxicity Profile of the Novel Begev Regimen (Bendamustine, Gemcitabine And Vinorelbine) Used As Salvage Therapy Prior to Autologous Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma

The Prognostic Role of Cell of Origin Profile and Myc Expression Assessed By Immunohistochemistry in Young High-Risk Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Results of First-Line Randomized BIO-DLCL04 Trial of Fondazione Italiana Linfomi (FIL)

Outcome of Transformed Marginal Zone Lymphomas Treated in the Rituximab Era

Utility of baseline 18FDG-PET/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma

Non-Hodgkin's Lymphomas Associated With Positive Hepatitis-C Virus Infection: A Prospective Multicentric Observational Study On Behalf Of The “Rete Ematologica Lombarda/Hematology Network Of Lombardia Region”

Do Leukemic Cells and Mesenchymal Stem Cells (MSCs) From AML Patients Share The Same Chromosomal Defect? A Cytogenetics, FISH and aCGH/Snpa Study

MYD88 (L265P) mutation is an independent risk factor for progression in patients with IgM monoclonal gammopathy of undetermined significance

Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenström’s macroglobulinemia and related lymphoid neoplasms

Clinical Significance of Tumor-Associated Macrophages in Early-Stage Hodgkin's Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only